Miller Fisher syndrome is an acute inflammatory polyradiculoneuropathy that is generally considered a variant of Guillain-Barré syndrome and is characterized by the clinical triad of ataxia, areflexia, and ophthalmoplegia. Several reports of familial Guillain-Barré syndrome have been reported, indicating a possible underlying genetic and/or environmental predisposition to the development of Guillain-Barré syndrome. A familial association in Miller Fisher syndrome has not previously been described in the literature. We report 2 cases of Miller Fisher syndrome presenting simultaneously in siblings, with a review of recent relevant literature.
Geleijns K., Brouwer BA, Jacobs BC, Houwing-Duistermaat JJ, van Duijn CM, van Doorn PAThe occurrence of Guillain-Barre syndrome within families. Neurology. 2004;63:1747-1750.
6.
Ropper AHThe Guillain-Barre syndrome. N Engl J Med. 1992; 326:1130-1136.
7.
Mori M., Kuwabara S., Fukutake T., Yuki N., Hattori T.Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104-1106.
8.
Blasetti A., Cerruto M., Cutarella R., et al. Miller Fisher syndrome and escherichia coli infection: is it a novel association? J Child Neurol. 2007;22:71-73.
9.
Odaka M., Yuki N., Hirata K.Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry. 2001;70:50-55.
10.
Kaida K., Kanzaki M., Morita D., et al. Anti-ganglioside complex antibodies in Miller Fisher syndrome . J Neurol Neurosurg Psychiatry. 2006;77:1043-1046.
11.
O’Hanlon G., Plomp J., Chakrabarti M., et al. Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain. 2001;124:893-906.
12.
Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I.Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997;745:32-36.
13.
Nishimoto Y., Odaka M., Hirata K., Yuki N.Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination. J Neuroimmunol. 2004; 148:200-205.
14.
Stangel M., Hartung HP, Marx P., Gold R.Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci. 1998;153:203-214.
15.
Zifko U., Drlicek M., Senautka G., Grisold W.High dose immunoglobulin therapy is effective in the Miller Fisher syndrome . J Neurol. 1994;241:178-179.
16.
Arakawa Y., Yoshimura M., Kobayashi S., et al. The use of intravenous immunoglobulin in Miller Fisher syndrome . Brain Dev. 1993;15:231-233.
17.
Mori M., Kuwabara S., Fukutake T., Hattori T.Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007;68:1144-1146.
18.
Bar-Joseph G., Etzioni A., Hemli J., Gershoni-Baruch R.Guillain-Barré syndrome in three siblings less than 2 years old. Arch Dis Child. 1991;66:1078-1079.
Margairaz A. , Poyart C.‘‘Familial’’ form of spontaneously resolving acute polyradiculo-neuritis: apropos of 2 cases of Guillain-Barre syndrome simultaneously observed in 2 brothers. Rev Neurol (Paris). 1965;113:475-479.
21.
Saunders M. , Rake M.Familial Guillain-Barre syndrome. Lancet. 1965;2:1106-1107.
22.
Korn-Lubetzki I., Steiner I.The occurrence of Guillain-Barré syndrome within families. Neurology. 2005;64:1665.
23.
Davis SJ, Salib R., Buchan H., Nilssen E.Miller Fisher syndrome: a diagnosis not to be missed. J Laryngol Otol. 2008;122:82-85.
24.
Lee JH, Sung IY, Rew ISClinical presentation and prognosis of childhood Guillain-Barré syndrome . J Paediatr Child Health. 2008;44:449-454.
